AI In Pharma How It Is Revolutionizing Clinical Writing For Faster FDA Approvals, Amar Drawid Guide
AI’s impact on clinical writing is revolutionizing the pharmaceutical industry, saving time and expediting the path to market.
In this episode, I’m joined by Amar Drawid, the Chief AI & Business Consulting Officer at Agilisium Consulting. Amar brings a wealth of experience in AI, machine learning, and bioinformatics from his roles at various pharmaceutical companies. We discuss the current trends in automating clinical writing, a significant demand area aimed at reducing the time spent on drafting documentation for FDA submissions.
Amar shares insights on how rapid first drafts can lead to quicker FDA approvals and faster market entry for drugs. We also tackle how to measure the return on investment for these innovations.
Tune in to learn how Amar’s expertise can help your organization stay ahead.
Specifically, this episode highlights the following themes:
- Automating clinical writing to accelerate FDA approvals.
- Measuring the return on investment through time reductions.
- Integrating business and technology for AI success
Links from this episode:
- Get to know more about Amar Drawid:https://www.linkedin.com/in/amardrawid
- Learn more about Agilisium Consulting: https://www.linkedin.com/in/amardrawid
- Get to know more about Steven Swan: https://www.linkedin.com/in/swangroup
==== Time Stamps ====
00:00 – Introduction
00:46 – About Amar Drawid
04:18 – Organizations are rapidly transitioning to generative AI
06:31 – Prioritize generative AI strategy and business value
09:42 – Amar needs clear goals and a strategy roadmap
14:18 – Growing trends in data analytics and digitization
18:58 – Economic incentive spurs investigation and potential action
20:33 – Increase revenue, cut costs, improve quality, consistency
23:22 – SMEs conduct iterative business reviews with clients
29:10 – Data operations will become increasingly automated, streamlined
32:31 – Automating clinical writing speeds up drug approval
